论文部分内容阅读
目的 探讨奈达铂单药节拍化疗同步放疗治疗中晚期食管癌的近期疗效和毒副反应.方法 74例65～78岁中晚期食管癌患者,36例(B组)行单纯放疗,6 MV-X线或者15 MV-X线常规放疗,2.0 Gy/次,每周5次,持续6～7周.38例(A组)自放疗之日起加用奈达铂30～40 mg,每周一次,共6次.治疗结束后评价毒副反应,3个月评价近期疗效.结果 A组完全缓解(CR)20例(52.6%),部分缓解(PR)14例(32.8 0A),临床总有效率(CR+PR)89.5%,明显高于B组的72.0%(P<0.05).而骨髓抑制及消化道毒副反应均较轻,患者可以耐受.结论 奈达铂化疗同步放疗治疗老年中晚期食管癌近期疗效较好,毒副反应可以耐受.“,”Objective To observe the short-term outcomes of nedaplatin with concurrent radiotherapy in elder patients with middle or advanced esophageal cancer. Methods Of 74 patients (aged 65 to 78 years old) with middle or advanced esophageal cancer, 36 cases(group B) were given conventional radiotherapy(6 MV-X ray or 15 MV-X ray, 2. 0 Gy×5 per week for 6 to 7 weeks), 38 cases(group A) were given additonal nedaplatin chemotherapy(30-40 mg once a week for 6 weeks). The clinical outcomes were evaluated 3 months after the treatment and adverse effects were recorded. Results Complete remission(CR) and partial remission(PR) in group A were seen in 20(52. 6%) cases and 14 (32. 8%) cases, respectively, with a total efficient rate(CR+PR) of 89. 5%, which was significantly higher than 72. 0% in group B (P<0. 05). Depression of marrow and adverse responses , of alimentary tract to nedaplatin with concurrent radiotheraphy were slight and torable. Conclusion The short-term outcomes of nedaplatin with concurrent radiotherapy are better and with torable adverse effects in elder patients with middle or advanced esophageal cancer.